PNC-27 is a synthetic peptide combining a p53-derived HDM-2-binding segment with a membrane-penetrating segment, studied in cancer research for selectively forming pores in cancer-cell membranes while sparing normal cells.
Animal/cell data only
PNC-27 is a 32-amino-acid lab-designed peptide fusing a fragment of the p53 tumor-suppressor protein to a membrane-penetrating sequence. In cell studies, it selectively kills cancer cells (not normal cells) by binding membrane-expressed HDM-2 and forming pores that cause cell lysis, with more recent work also showing mitochondrial disruption in cancer cells. This is genuinely interesting cancer-biology research — entirely at the cell-culture level. It is a research compound only, with no human clinical trials and no regulatory approval.
What is PNC-27 researched for?+
Selective cancer-cell destruction, primarily in cell-culture (in-vitro) cancer research.
How is PNC-27 different from typical chemotherapy mechanisms?+
It is studied for a membrane pore-forming mechanism that kills susceptible cancer cells directly, rather than the intracellular apoptosis pathways most chemotherapy drugs rely on.
Is PNC-27 an approved cancer treatment?+
No. It remains a research compound studied in preclinical models and is not an approved therapy.
How does it actually target cancer cells specifically?+
Through a marker that's mostly unique to cancer cells. It binds to HDM2 (also called MDM2), a protein that shows up on the outer membrane of certain cancer cells but not normal healthy cells — and once bound, it creates actual pores in that membrane, causing the cancer cell to rupture.
Does it also do anything once inside the cell?+
Yes — beyond the initial membrane pore effect, it also gets inside the cancer cell and disrupts mitochondrial membranes directly, giving it two separate mechanisms working against the same cell.
Looking for something specific, or placing a wholesale order? Send us a DM or email.